PharmaCyte Biotech Inc (PMCB)
2.155
-0.02
(-0.99%)
USD |
NASDAQ |
May 10, 16:00
2.16
0.00 (0.00%)
After-Hours: 20:00
PharmaCyte Biotech Net Income (Quarterly): -0.6195M for Jan. 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| January 31, 2024 | -0.6195M |
| October 31, 2023 | 2.790M |
| July 31, 2023 | -3.183M |
| April 30, 2023 | -0.1263M |
| January 31, 2023 | -0.7641M |
| October 31, 2022 | -1.880M |
| July 31, 2022 | -1.545M |
| April 30, 2022 | -1.423M |
| January 31, 2022 | -0.8113M |
| October 31, 2021 | -0.9797M |
| July 31, 2021 | -1.025M |
| April 30, 2021 | -0.96M |
| January 31, 2021 | -0.7571M |
| October 31, 2020 | -0.9502M |
| July 31, 2020 | -0.8839M |
| April 30, 2020 | -0.7504M |
| January 31, 2020 | -0.8753M |
| October 31, 2019 | -1.067M |
| July 31, 2019 | -1.134M |
| April 30, 2019 | -1.139M |
| January 31, 2019 | -0.6763M |
| October 31, 2018 | -1.037M |
| July 31, 2018 | -1.215M |
| April 30, 2018 | -1.296M |
| January 31, 2018 | -2.031M |
| Date | Value |
|---|---|
| October 31, 2017 | -1.814M |
| July 31, 2017 | -1.688M |
| April 30, 2017 | -1.155M |
| January 31, 2017 | -1.282M |
| October 31, 2016 | -0.9746M |
| July 31, 2016 | -1.032M |
| April 30, 2016 | -1.122M |
| January 31, 2016 | -1.791M |
| October 31, 2015 | -1.636M |
| July 31, 2015 | -1.515M |
| April 30, 2015 | -2.821M |
| January 31, 2015 | -1.458M |
| October 31, 2014 | -4.064M |
| July 31, 2014 | -1.585M |
| April 30, 2014 | -16.47M |
| January 31, 2014 | -0.4588M |
| October 31, 2013 | -5.658M |
| July 31, 2013 | -4.666M |
| April 30, 2013 | -0.3272M |
| January 31, 2013 | -0.3768M |
| October 31, 2012 | -0.3828M |
| July 31, 2012 | -0.5105M |
| April 30, 2012 | -0.5044M |
| January 31, 2012 | -0.2718M |
| October 31, 2011 | -0.4372M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-3.183M
Minimum
Jul 2023
2.790M
Maximum
Oct 2023
-0.8919M
Average
-0.9502M
Median
Oct 2020
Net Income (Quarterly) Benchmarks
| CEL-SCI Corp | -6.710M |
| AIM ImmunoTech Inc | -12.58M |
| IGC Pharma Inc | -5.589M |
| NovaBay Pharmaceuticals Inc | -4.108M |
| Protalix BioTherapeutics Inc | -6.044M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 1.869M |
| EPS Diluted (Quarterly) | -0.65 |
| Enterprise Value | -25.45M |
| Earnings Yield | -55.68% |
| Normalized Earnings Yield | -701.32 |